These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36572177)

  • 1. The role of adenosine A
    Launay A; Nebie O; Vijaya Shankara J; Lebouvier T; Buée L; Faivre E; Blum D
    Neuropharmacology; 2023 Mar; 226():109379. PubMed ID: 36572177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.
    Laurent C; Burnouf S; Ferry B; Batalha VL; Coelho JE; Baqi Y; Malik E; Mariciniak E; Parrot S; Van der Jeugd A; Faivre E; Flaten V; Ledent C; D'Hooge R; Sergeant N; Hamdane M; Humez S; Müller CE; Lopes LV; Buée L; Blum D
    Mol Psychiatry; 2016 Jan; 21(1):97-107. PubMed ID: 25450226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiological Role and Medicinal Chemistry of A
    Merighi S; Borea PA; Varani K; Vincenzi F; Travagli A; Nigro M; Pasquini S; Suresh RR; Kim SW; Volkow ND; Jacobson KA; Gessi S
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of adenosine A
    Silva AC; Lemos C; Gonçalves FQ; Pliássova AV; Machado NJ; Silva HB; Canas PM; Cunha RA; Lopes JP; Agostinho P
    Neurobiol Dis; 2018 Sep; 117():72-81. PubMed ID: 29859867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor.
    Carvalho K; Faivre E; Pietrowski MJ; Marques X; Gomez-Murcia V; Deleau A; Huin V; Hansen JN; Kozlov S; Danis C; Temido-Ferreira M; Coelho JE; Mériaux C; Eddarkaoui S; Gras SL; Dumoulin M; Cellai L; ; Landrieu I; Chern Y; Hamdane M; Buée L; Boutillier AL; Levi S; Halle A; Lopes LV; Blum D
    Brain; 2019 Nov; 142(11):3636-3654. PubMed ID: 31599329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synaptic and memory dysfunction in a β-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine.
    Gonçalves FQ; Lopes JP; Silva HB; Lemos C; Silva AC; Gonçalves N; Tomé ÂR; Ferreira SG; Canas PM; Rial D; Agostinho P; Cunha RA
    Neurobiol Dis; 2019 Dec; 132():104570. PubMed ID: 31394204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aβ
    Dias L; Madeira D; Dias R; Tomé ÂR; Cunha RA; Agostinho P
    Cell Mol Life Sci; 2022 Jul; 79(8):457. PubMed ID: 35907034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease.
    Cellai L; Carvalho K; Faivre E; Deleau A; Vieau D; Buée L; Blum D; Mériaux C; Gomez-Murcia V
    Front Neurosci; 2018; 12():520. PubMed ID: 30123104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Adenosine A
    Madeira D; Dias L; Santos P; Cunha RA; Canas PM; Agostinho P
    Mol Neurobiol; 2021 Dec; 58(12):6232-6248. PubMed ID: 34476674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic Dysfunction in Alzheimer's Disease: Aβ, Tau, and Epigenetic Alterations.
    Li K; Wei Q; Liu FF; Hu F; Xie AJ; Zhu LQ; Liu D
    Mol Neurobiol; 2018 Apr; 55(4):3021-3032. PubMed ID: 28456942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine receptor signalling in Alzheimer's disease.
    Trinh PNH; Baltos JA; Hellyer SD; May LT; Gregory KJ
    Purinergic Signal; 2022 Sep; 18(3):359-381. PubMed ID: 35870032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A
    Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
    Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.
    Lee CC; Chang CP; Lin CJ; Lai HL; Kao YH; Cheng SJ; Chen HM; Liao YP; Faivre E; Buée L; Blum D; Fang JM; Chern Y
    Mol Neurobiol; 2018 Dec; 55(12):8936-8952. PubMed ID: 29616397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
    Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
    Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of adenosine A
    Li XC; Hong FF; Tu YJ; Li YA; Ma CY; Yu CY; Fang L; Chen JY; Li ZL; Bao SJ; Zhang ZL; Ying HY; Gyabaah AT; Hu SY; Shao GH; Cai XH
    Exp Neurol; 2022 Apr; 350():113929. PubMed ID: 34813840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
    Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
    Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.